In an effort to improve price transparency, the Trump administration on Wednesday announced a final rule requiring drug manufacturers to disclose their list prices for pharmaceutical products or biologics in television ads for drugs covered by Medicare or Medicaid if the wholesale acquisition cost is $35 or more for a month’s supply. Affected drugs include adalimumab (Humira), with its wholesale acquisition cost (WAC) of $5174 per month, and etanercept (Enbrel), with its WAC of $5174 per month.
In an effort to improve price transparency, the Trump administration on Wednesday announced a final rule requiring drug manufacturers to disclose their list prices for pharmaceutical products or biologics in television ads for drugs covered by Medicare or Medicaid if the wholesale acquisition cost (WAC) is $35 or more for a month’s supply.
HHS said the rule, part of the administration’s blueprint to lower drug prices, aims to improve the quality, accessibility, and affordability of government healthcare programs.
In its document explaining the rule, HHS said the lack of price information leads to “to inefficient utilization of prescription drugs or biological products.” However, the department also acknowledged that, while it expects the change “to put downward pressure on the list prices of drugs, we cannot quantify the level of this impact because there is not data or examples that we can use.”
Instead, the department is relying on the idea that disclosing prices in television ads—but not other media, such as magazine or internet ads—would correct what it calls a market failure and induce greater competition.
It also said that patients, once they know more about the price of their treatments, might discuss less expensive alternatives with their doctor or pharmacist.
The department included a table of the 20 drugs with the highest television advertising expenditures in 2016. The average WAC for the drugs is $3473 (range: $189.00-$16,937.91) per month.
Included on the list are palbociclib (Ibrance), a Pfizer drug for HR-positive and HER2-negative breast cancer, with a WAC of $16,938 a month; originator adalimumab (Humira), with a WAC of $5174 per month; and originator etanercept (Enbrel), with a WAC of $5174 per month.
In comments he made Wednesday, HHS Secretary Alex Azar said while some patients might pay less for certain drugs, others, especially for those with high-deductible health plans or on Medicare Part D, the list price is the price they will pay. This also applies to people who must take high-cost, specialty pharmaceuticals, where they are responsible for coinsurance as well as copays.
Since prices will vary depending on health insurance, the television ads must include a statement that costs may differ based on coverage. By just listing the price in the ad, it will not require review by the FDA Office of Prescription Drug Promotion.
If a drug company fails to include the required information in their ad, therefore suggesting their drug is under the $35 threshold, a competitor can bring forward a lawsuit under the Lanham Act, also known as the Trademark Act of 1946, which bars false advertising.
Responding to claims from manufacturers that the rule will infringe on First Amendment rights, Azar emphasized that the administration believes there is no problem with requiring prices in ads that are telling patients to go to their doctor and ask about a drug.
However, the Biotechnology Innovation Organization thinks the move is not enough to help patients have informed discussions about price and access and instead will likely confuse them. A spokesman from the organization said, "We continue to believe that more comprehensive and meaningful transparency measures, ones which provide patients with contextualized prescription drug cost information that is relevant to them, rather than simply a list price that is not reflective of most patients' likely out-of-pocket costs, will best meet the administration's goals of helping patients become better informed and empowered in their healthcare decision making."
But Matt Eyles, president and chief executive officer of America’s Health Insurance Plans, issued a statement praising the decision. “We commend the administration for taking an important step to shed some light on the ‘black box’ of drug pricing. When patients have a clear view into list prices, which are set and controlled solely by drug makers, they are better empowered to make healthcare decisions that are right for them,” he said.
The rule will go into effect 60 days after being published in the Federal Register.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.